This study is looking into whether vortioxetine, a medication, can help improve mood and thinking problems in people with early-stage behavioral variant Frontotemporal Dementia (bvFTD). Researchers want to see if people with bvFTD and mood issues have different brain changes and thinking patterns compared to those without bvFTD. They also aim to find out if vortioxetine treatment leads to improvements in mood and thinking, and if there are any related changes in the brain. The study plans to enroll 50 participants who are 45 years or older and have a diagnosis of bvFTD with symptoms like depression, anxiety, irritability, or agitation.

Study design

This interventional study plans to enroll 50 participants. Individuals with bvFTD and mood symptoms will receive approximately 12 weeks of treatment with vortioxetine.

What's involved

Participants will have a screening visit with clinical assessments and lab tests. They will also undergo an initial brain MRI and FDG PET scan.

Compensation

Not stated in the trial record.

Follow-up

Brain changes will be measured at the beginning of the study (Baseline) and after 12 weeks of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.